Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Levopraid
2. N-(((s)-1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide
3. Rv-12309
1. 23672-07-3
2. (s)-(-)-sulpiride
3. (-)-sulpiride
4. Levopraid
5. S-(-)-sulpiride
6. Levobren
7. Levopride
8. L-sulpiride
9. (s)-sulpiride
10. Lesuride
11. Levosulpirida
12. Levosulpiridum
13. Levosulpiride [inn]
14. Rv-12309
15. Sulpiride L-form
16. N-{[(2s)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxy-5-sulfamoylbenzamide
17. Sulpiride, (s)-
18. Sulpiride, (-)-
19. (s)-(-)-5-aminosulfonyl-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide
20. Jtg7r315lk
21. Chebi:64119
22. (-)-n-(((s)-1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide
23. (s)-(-)-n-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-o-anisamide
24. N-[[(2s)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide
25. S-(-)-n-(1-ethyl-2-pyrrolidinomethyl)-2-methoxy-5-sulfamoylebenzamide
26. Levosulpiride (inn)
27. Ncgc00024853-05
28. Levosulpiridum [inn-latin]
29. Dsstox_cid_22583
30. Dsstox_rid_80052
31. Dsstox_gsid_42583
32. Levosulpirida [inn-spanish]
33. Nexipride
34. Smr000466366
35. Cas-23672-07-3
36. (s)-n-((1-ethylpyrrolidin-2-yl)methyl)-2-methoxy-5-sulfamoylbenzamide
37. Sulpiride,(+)
38. Unii-jtg7r315lk
39. C15h23n3o4s
40. Levogastrol
41. Sulpiride-l
42. Sulpiride-s
43. Benzamide, 5-(aminosulfonyl)-n-(((2s)-1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-
44. Benzamide, 5-(aminosulfonyl)-n-[[(2s)-1-ethyl-2-pyrrolidinyl]methyl]-2-methoxy-
45. Levopraid (tn)
46. Cas-15676-16-1
47. Mfcd00055220
48. Tocris-0895
49. Sulpiride [l-(-)]
50. Biomol-nt_000030
51. (s)-5-aminosulfonyl-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide
52. Levosulpiride (levogastrol)
53. Lopac0_001089
54. Schembl70112
55. Gtpl958
56. Mls000759490
57. Mls001424014
58. Levosulpiride [mart.]
59. Levosulpiride [who-dd]
60. Sulpiride L-form [mi]
61. Bpbio1_001221
62. Chembl267044
63. (s)-n-[(1-ethylpyrrolidin-2-yl)methyl]-2-methoxy-5-sulfamoylbenzamide
64. Dtxsid0042583
65. Bdbm81774
66. Zinc57008
67. Hms2051a08
68. Hms2089e04
69. Hms2232p10
70. Hms3263i20
71. Hms3266p14
72. Hms3411d20
73. Hms3675d20
74. Hms3884h07
75. Hy-b1059
76. Tox21_110933
77. Tox21_501089
78. Pdsp1_000516
79. Pdsp1_000620
80. Pdsp1_001649
81. Pdsp2_000514
82. Pdsp2_000616
83. S2104
84. Akos007930553
85. Akos015897363
86. Tox21_110933_1
87. Ac-6821
88. Bcp9000853
89. Ccg-100847
90. Cs-4581
91. Ks-5103
92. Lp01089
93. Nc00097
94. Sdccgsbi-0051059.p002
95. Benzamide, 5-(aminosulfonyl)-n-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-, (s)-
96. Benzamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-2-methoxy-5-sulfamoyl-, S-(-)-
97. Ncgc00015966-10
98. Ncgc00016718-01
99. Ncgc00024853-01
100. Ncgc00024853-02
101. Ncgc00024853-03
102. Ncgc00024853-04
103. Ncgc00024853-06
104. Ncgc00024853-09
105. Ncgc00024853-11
106. Ncgc00261774-01
107. Bl166176
108. Bcp0726000072
109. Cas_15676-16-1
110. (s)-(-)-sulpiride, >=98% (titration)
111. Eu-0101089
112. I0821
113. Sw197477-2
114. D07312
115. H11356
116. S 7771
117. Ab00639965-06
118. Ab00639965-08
119. Ab00639965_09
120. 672l073
121. A816834
122. Sr-01000076136
123. Sr-01000597436
124. J-015181
125. Q1452256
126. Sr-01000076136-2
127. Sr-01000597436-1
128. Brd-k51671335-001-01-5
129. Brd-k51671335-001-04-9
130. (s)-(-)-sulpiride, Vetranal(tm), Analytical Standard
131. N-[(1-ethylpyrrolidin-2-yl)methyl]-5-methoxy-2-sulfamoyl-benzamide
132. (-)-5-aminosulfonyl-n-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide
133. O-anisamide, N-((1-ethyl-2-pyrrolidinyl)methyl)-5-sulfamoyl-, (s)-(-)-
134. 5-ht6 Serotonin Receptor From Rat, Recombinant, Expressed In Hek 293 Cells, Membrane Suspension
| Molecular Weight | 341.4 g/mol |
|---|---|
| Molecular Formula | C15H23N3O4S |
| XLogP3 | 0.6 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 6 |
| Exact Mass | 341.14092740 g/mol |
| Monoisotopic Mass | 341.14092740 g/mol |
| Topological Polar Surface Area | 110 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 505 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
N - Nervous system
N05 - Psycholeptics
N05A - Antipsychotics
N05AL - Benzamides
N05AL07 - Levosulpiride
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
75
PharmaCompass offers a list of Levosulpiride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Levosulpiride manufacturer or Levosulpiride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Levosulpiride manufacturer or Levosulpiride supplier.
PharmaCompass also assists you with knowing the Levosulpiride API Price utilized in the formulation of products. Levosulpiride API Price is not always fixed or binding as the Levosulpiride Price is obtained through a variety of data sources. The Levosulpiride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Levopride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levopride, including repackagers and relabelers. The FDA regulates Levopride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levopride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Levopride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Levopride supplier is an individual or a company that provides Levopride active pharmaceutical ingredient (API) or Levopride finished formulations upon request. The Levopride suppliers may include Levopride API manufacturers, exporters, distributors and traders.
click here to find a list of Levopride suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Levopride Drug Master File in Korea (Levopride KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Levopride. The MFDS reviews the Levopride KDMF as part of the drug registration process and uses the information provided in the Levopride KDMF to evaluate the safety and efficacy of the drug.
After submitting a Levopride KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Levopride API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Levopride suppliers with KDMF on PharmaCompass.
A Levopride written confirmation (Levopride WC) is an official document issued by a regulatory agency to a Levopride manufacturer, verifying that the manufacturing facility of a Levopride active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Levopride APIs or Levopride finished pharmaceutical products to another nation, regulatory agencies frequently require a Levopride WC (written confirmation) as part of the regulatory process.
click here to find a list of Levopride suppliers with Written Confirmation (WC) on PharmaCompass.
Levopride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levopride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levopride GMP manufacturer or Levopride GMP API supplier for your needs.
A Levopride CoA (Certificate of Analysis) is a formal document that attests to Levopride's compliance with Levopride specifications and serves as a tool for batch-level quality control.
Levopride CoA mostly includes findings from lab analyses of a specific batch. For each Levopride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levopride may be tested according to a variety of international standards, such as European Pharmacopoeia (Levopride EP), Levopride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levopride USP).
